Highlights
NASDAQ: TGTX       Tg Therapeuticscmn
Last Price Today's Change   Day's Range   Trading Volume
20.09   -0.22 (1.08%)  19.75 - 20.76  1,645,800

Overview

 
Avg Volume (4 weeks):1,746,147
4 Weeks Range:16.56 - 20.76
4 Weeks Price Volatility (%):
84.05%
52 Weeks Range:4.95 - 22.28
52 Weeks Price Volatility (%):
87.36%
Average Price Target: 8.00
Price Target Upside/Downside: -12.09

Headlines



No recent Headlines for this stock.


Business Background

TG Therapeutics Inc is a U.S. biopharmaceutical company focused on the development and commercialization of B-cell malignancies and autoimmune disease treatments. The pipeline includes two treatments targeting hematological malignancies and autoimmune diseases: TG-1101 (ublituximab), a glycoengineered monoclonal antibody; and TGR-1202, an orally available PI3K delta inhibitor for various hematologic malignancies. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 now entering clinical development for autoimmune disorders. The company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies.

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
 
 

2452  5804  513  138 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 ZOM 0.168-0.057 
 GNUS 3.55+1.24 
 NIO 9.38+1.47 
 LK 1.38-1.62 
 SOLO 3.13+0.80 
 WKHS 20.91+1.73 
 AAL 12.50-0.31 
 JOB 1.50+0.986 
 SQQQ 7.14-0.15 
 GE 6.82+0.08 
Partners & Brokers